Arca
Skip to content
Tools
Tools

Lymphangioleiomyomatosis

Drug research and approvals for lymphangioleiomyomatosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 9 studies of lymphangioleiomyomatosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 4 approved and 2 open orphan designations naming it.

  • Recruiting worldwide: 9
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 4
  • EU medicines: 0

Recruiting now

Newest posted first, of 9 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 1

Phase 2 7

Phase 1 or earlier 3

How its trials ended

47 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 11 whose ending is known, 73% met their primary endpoint, 9% missed it and 18% stopped early.

  • Completed, result not reported1838%
  • Ongoing1430%
  • Met its primary endpoint817%
  • Status unknown49%
  • Missed its primary endpoint12%
  • Stopped: sponsor or business decision12%
  • Stopped: other or unclear12%

FDA orphan designations

Approved first, then open designations, newest first
Apr 10, 2018AfinitorFor the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated…Novartis Pharmaceuticals Corp.Approved
May 28, 2015RapamuneTreatment of lymphangioleiomyomatosis (LAM)Pfizer, Inc.Approved
Apr 26, 2012AfinitorTreatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery.Novartis Pharmaceuticals Corp.Approved
Oct 29, 2010AfinitorTreatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic…Novartis Pharmaceuticals Corp.Approved
Nov 17, 2014SirolimusTreatment of lymphangioleiomyomatosisCote Orphan Consulting, LLCDesignated
Jun 25, 2014SirolimusTreatment of lymphangioleiomyomatosisLAM Therapeutics, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.